These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 38728915)
1. D-serine and D-amino acid oxidase levels in patients with schizophrenia spectrum disorders in the first episode and 6-month follow-up. Uzun Uysal E; Tomruk NB; Çakır Şen C; Yıldızhan E J Psychiatr Res; 2024 Jul; 175():123-130. PubMed ID: 38728915 [TBL] [Abstract][Full Text] [Related]
2. Identification of multiple serine racemase (SRR) mRNA isoforms and genetic analyses of SRR and DAO in schizophrenia and D-serine levels. Yamada K; Ohnishi T; Hashimoto K; Ohba H; Iwayama-Shigeno Y; Toyoshima M; Okuno A; Takao H; Toyota T; Minabe Y; Nakamura K; Shimizu E; Itokawa M; Mori N; Iyo M; Yoshikawa T Biol Psychiatry; 2005 Jun; 57(12):1493-503. PubMed ID: 15953485 [TBL] [Abstract][Full Text] [Related]
3. Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging. Lin CH; Yang HT; Chiu CC; Lane HY Sci Rep; 2017 Nov; 7(1):14849. PubMed ID: 29093468 [TBL] [Abstract][Full Text] [Related]
4. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054 [TBL] [Abstract][Full Text] [Related]
5. Blood D-Amino Acid Oxidase Levels Increased With Cognitive Decline Among People With Mild Cognitive Impairment: A Two-Year Prospective Study. Lin CH; Lane HY Int J Neuropsychopharmacol; 2022 Aug; 25(8):660-665. PubMed ID: 35430632 [TBL] [Abstract][Full Text] [Related]
7. Different serine and glycine metabolism in patients with schizophrenia receiving clozapine. Hons J; Vasatova M; Cermakova E; Doubek P; Libiger J J Psychiatr Res; 2012 Jun; 46(6):811-8. PubMed ID: 22502820 [TBL] [Abstract][Full Text] [Related]
8. The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia. Abou El-Magd RM; Park HK; Kawazoe T; Iwana S; Ono K; Chung SP; Miyano M; Yorita K; Sakai T; Fukui K J Psychopharmacol; 2010 Jul; 24(7):1055-67. PubMed ID: 19329549 [TBL] [Abstract][Full Text] [Related]
9. Retinal NMDA receptor function and expression are altered in a mouse lacking D-amino acid oxidase. Gustafson EC; Morgans CW; Tekmen M; Sullivan SJ; Esguerra M; Konno R; Miller RF J Neurophysiol; 2013 Dec; 110(12):2718-26. PubMed ID: 24068757 [TBL] [Abstract][Full Text] [Related]
10. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Heresco-Levy U; Javitt DC; Ebstein R; Vass A; Lichtenberg P; Bar G; Catinari S; Ermilov M Biol Psychiatry; 2005 Mar; 57(6):577-85. PubMed ID: 15780844 [TBL] [Abstract][Full Text] [Related]
11. Identification of novel D-amino acid oxidase inhibitors by in silico screening and their functional characterization in vitro. Katane M; Osaka N; Matsuda S; Maeda K; Kawata T; Saitoh Y; Sekine M; Furuchi T; Doi I; Hirono S; Homma H J Med Chem; 2013 Mar; 56(5):1894-907. PubMed ID: 23391306 [TBL] [Abstract][Full Text] [Related]
12. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807 [TBL] [Abstract][Full Text] [Related]
13. Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment. Yamamori H; Hashimoto R; Fujita Y; Numata S; Yasuda Y; Fujimoto M; Ohi K; Umeda-Yano S; Ito A; Ohmori T; Hashimoto K; Takeda M Neurosci Lett; 2014 Oct; 582():93-8. PubMed ID: 25218715 [TBL] [Abstract][Full Text] [Related]
14. High dose D-serine in the treatment of schizophrenia. Kantrowitz JT; Malhotra AK; Cornblatt B; Silipo G; Balla A; Suckow RF; D'Souza C; Saksa J; Woods SW; Javitt DC Schizophr Res; 2010 Aug; 121(1-3):125-30. PubMed ID: 20541910 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Antipsychotic Drugs for 24-Month Maintenance Treatment in First-Episode Schizophrenia: Evidence From a Community-Based "Real-World" Study. Zhang C; Chen MJ; Wu GJ; Wang ZW; Rao SZ; Zhang Y; Yi ZH; Yang WM; Gao KM; Song LS J Clin Psychiatry; 2016 Nov; 77(11):e1460-e1466. PubMed ID: 28076667 [TBL] [Abstract][Full Text] [Related]
16. D-amino acid oxidase activity is inhibited by an interaction with bassoon protein at the presynaptic active zone. Popiolek M; Ross JF; Charych E; Chanda P; Gundelfinger ED; Moss SJ; Brandon NJ; Pausch MH J Biol Chem; 2011 Aug; 286(33):28867-28875. PubMed ID: 21700703 [TBL] [Abstract][Full Text] [Related]
17. Potential pathophysiological role of D-amino acid oxidase in schizophrenia: immunohistochemical and in situ hybridization study of the expression in human and rat brain. Ono K; Shishido Y; Park HK; Kawazoe T; Iwana S; Chung SP; Abou El-Magd RM; Yorita K; Okano M; Watanabe T; Sano N; Bando Y; Arima K; Sakai T; Fukui K J Neural Transm (Vienna); 2009 Oct; 116(10):1335-47. PubMed ID: 19685198 [TBL] [Abstract][Full Text] [Related]
18. Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial. Lin CH; Lin CH; Chang YC; Huang YJ; Chen PW; Yang HT; Lane HY Biol Psychiatry; 2018 Sep; 84(6):422-432. PubMed ID: 29397899 [TBL] [Abstract][Full Text] [Related]
19. The neurobiology of D-amino acid oxidase and its involvement in schizophrenia. Verrall L; Burnet PW; Betts JF; Harrison PJ Mol Psychiatry; 2010 Feb; 15(2):122-37. PubMed ID: 19786963 [TBL] [Abstract][Full Text] [Related]